Systems Biology Approach to SARS-CoV-2 Infection in Individuals with known COVID-19 Contacts: A Prospective Cohort Study

项目摘要/摘要 有了这个K38导师激励研究机会驻留过渡学者(STARRTS)奖，我 将培养必要的技能，成为一名独立资助的临床医生兼科学家，在 免疫学、系统生物学和疫苗学的交叉学科。我对翻译的长期承诺 而临床研究为我的这项工作提供了基础。在这个奖项中，我将得到博士的指导。 Nadine Rouphael，翻译免疫学专家，希望诊所的临时主任 埃默里疫苗中心的巴利·普伦德兰博士是斯坦福大学的系统生物学专家。 艾琳·谢勒，B细胞生物学专家，希望诊所疫苗和治疗评估股主任 (VTEU)研究实验室，和克里斯蒂娜·梅塔博士，应用生物统计学专家 埃默里大学罗林斯公共卫生学院的生物统计学和生物信息学。我会亲自动手的 临床研究和生物统计学培训以及与系统生物学有关的实验室方法培训， 并将参加实地讲习班。目前，我正在为我的R38研究年注册科目，并使用 抗SARS-CoV-2 IgM/Ig G检测和症状驱动的SARS-CoV-2聚合酶链式反应联合诊断方法 检测以更好地识别无症状和轻度新冠肺炎患者。我们假设一个系统 生物学方法将确定预测新冠肺炎病的特定基线免疫学特征 获得性和严重性，轻度和无症状的新冠肺炎将具有特定的先天和 适应性免疫反应。我们建议进行一项队列研究，以完成以下目标：1)确定基线 免疫标志物预测新冠肺炎疾病的获得和严重程度，以及2)表征先天 无症状和轻度症状个体对SARS-CoV-2的获得性免疫反应 新冠肺炎。完成这些目标将使我更好地理解新冠肺炎，并使我能够 作为一名临床医生兼科学家过渡到独立。

PROJECT SUMMARY/ABSTRACT With this K38 Mentored Stimulating Access to Research in Residency Transition Scholar (StARRTS) award, I will develop the necessary skills to become an independently funded clinician-scientist, working at the intersection of immunology, systems biology, and vaccinology. My longstanding commitment to translational and clinical research provides me with the foundation for this work. During this Award, I will be mentored by Dr. Nadine Rouphael, an expert in translational immunology, who is interim director of the Hope Clinic, the clinical arm of the Emory Vaccine Center, Dr. Bali Pulendran, an expert in systems biology at Stanford University, Dr. Erin Scherer, an expert in B-cell biology and director of the Hope Clinic Vaccine and Treatment Evaluation Unit (VTEU) Research Laboratory, and Dr. Christina Mehta, an expert in applied biostatistics in the Department of Biostatistics and Bioinformatics at the Rollins School of Public Health of Emory University. I will have hands on clinical research and biostatistical training as well as training in laboratory methods related to systems biology, and will attend workshops in the field. Currently, I am enrolling subjects for my R38 research year and using the combined diagnostic methods of anti-SARS-CoV-2 IgM/IgG testing and symptom-driven SARS-CoV-2 PCR testing to better identify individuals with asymptomatic and mild COVID-19. We hypothesize that a systems biology approach will identify specific baseline immunologic signatures, which predict COVID-19 disease acquisition and severity and that mild and asymptomatic COVID-19 will be characterized by a specific innate and adaptive immune responses. We propose a cohort study to complete the following aims: 1) To identify baseline immunologic markers predictive of COVID-19 disease acquisition and severity, and 2) To characterize the innate and adaptive immune responses to SARS-CoV-2 in individuals with asymptomatic and mildly symptomatic COVID-19. Completion of these aims will provide a better understanding of COVID-19 and position me to transition to independence as a clinician-scientist.